Skip to content
Matrix Global Advisors
Matrix Global Advisors
  • Home
  • About
  • News
  • Our Work
  • Contact
  • Home
  • About
  • News
  • Our Work
  • Contact
Aug82019
Op-Eds

The Economics of Biologic Drugs

Alex Brill and Benedic N. Ippolito | Health Affairs Blog

The market for biologic drugs in the United States is large and growing. Total US biologic sales in 2018 is estimated to have been $125 billion, an increase of 50 percent since 2014. Given widespread public interest in curbing drug costs and drug spending, policymakers and others are keenly interested in the viability of biologic market competition to reduce prices.

Read Here

August 8, 2019Category: Op-Eds
Tags: economicshealth economicshealth policy

Post navigation

PreviousPrevious post:New MGA Paper Estimates Biosimilar Savings Opportunities for Large EmployersNextNext post:Debate Over Whether Biologics Constitute Natural Monopolies Continues
  • Analysis(27)
  • Books(2)
  • Events(13)
  • Interviews(33)
  • News(43)
  • Op-Eds(59)
  • Press Releases(2)
  • Testimony(18)
  • Almost-Speaker McCarthy
    November 23, 2020
  • Nursing Homes Prepare for Third COVID-19 Surge
    October 26, 2020
  • Impact of the Coronavirus Pandemic on Red, Blue, and Swing States
    October 20, 2020
  • Trump Roils Markets with Conflicting Statements on Pandemic Relief
    October 7, 2020

Website Design and Developed by DreamBig Creative